• Loading stock data…

Edwin Ngarari

Foamix Pharmaceuticals: A dermatology play with more than 100% upside potential

Foamix Pharmaceuticals (NASDAQ: FOMX) shares have been on a free fall for the past six months, declining by more than 30 percent to $2.3. The clinical-stage company which develops and commercializes … [Read more...] about Foamix Pharmaceuticals: A dermatology play with more than 100% upside potential

Aurinia Pharmaceuticals (NASDAQ: AUPH): Highly undervalued in light of Voclosporin’s blockbuster potential

Biotechnology stocks have delivered massive returns over the last few years. Apart from improving the lives of patients, newly developed drugs have made big profits for investors in the process. A … [Read more...] about Aurinia Pharmaceuticals (NASDAQ: AUPH): Highly undervalued in light of Voclosporin’s blockbuster potential